Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow... awesome Dan Goure. Thanks for sharing this incredible story sharpie510. This is what it's all about!
NB now I understand why the dogs are involved.in the story.
DAN (ASCO 2023)
Post 601979
THE BIG BIZ SHOW
PODCAST June 14, 2023
https://www.biztalkradio.com/players/individuals/
THE BIG BIZ SHOW
PODCAST June 14, 2023
https://www.biztalkradio.com/players/individuals/
antihama,
Kat Charles receives the DCVax-L vaccines from her oncologist - National Hospital for Neurology and Neurosurgery (NHNN) in Queen's Square, London.
Kat Charles
October 2022
Thanks for sharing sharpie510.
Jamil is a long term #glioblastoma survivor thanks to Dr. Liau and DCVax-L. Almost 11 YEARS!!
— rj (@sharpie510) June 14, 2023
👏👏👏👏👏
The DCVax® Platform For All Solid Tumor Cancers$nwbo #dcvax #gbm #cancermoonshot @potus
Against the Odds. Surviving Brain Cancer with Jamil Newirthhttps://t.co/SEIPmiKhBX
Thanks hoffmann.
$NWBO
— hoffmann6383 (@hoffmann6383) June 14, 2023
Lawsuit Update
As expected, @CohenMilstein responded within 2 days per the Judge's individual rules. They raise a number of substantive and procedural arguments against @citsecurities's request for a pre-motion conference for its anticipated Rule 11 sanctions.
First,… pic.twitter.com/cWeGf302Ze
biosectinvestor,
Click on 2 (NW Bio)/15( ASCO 2023) pictures
https://www.linkedin.com/feed/update/urn:li:activity:7074065751262781440/
DAN (ASCO 2023)
ALICE (ASCO 2023):
Sidi Lemine
CEO, Jade Kite
2d ago
In this article by @UCLAHealth, Dr. Linda Liau (Chair of Neurosurgery) and Dr. S. Thomas Carmichael (Chair of @UCLANeurology) were interviewed about FDA approvals for #glioblastoma and #Alzheimers treatments. Read the full article here: https://t.co/gTXyglrZPD pic.twitter.com/3Yg79XQoaW
— UCLA Neurosurgery 🧠 (@UCLANsgy) June 13, 2023
Laura was a shining light. My condolences to Nicola, Mark and Gracie @shitscaredmum pic.twitter.com/8Dl67O4WyL
— Siobhain McDonagh MP (@Siobhain_Mc) June 13, 2023
Thanks abeta.
We are anxiously awaiting approval to start using this therapy for our patients in the clinic, but we are not stopping here! There will be additional clinical trials for low grade #glioma using this therapy in combination with other therapies. Stay tune!#btsm https://t.co/zdvUll2fJD
— PhiOanh "Leia" NghiemPhu, MD (@Leia_N_MD) June 5, 2023
Would disagree about INDIGO
— Matt Williams (@matthwilliams) June 8, 2023
While it definitely shows that the drug has an effect, we don't know that the strategy of IDH-inhib in those who DO need RT is actually safe (i.e. OS the same)
Thanks for sharing abeta.
ATLnsider,
Google his name. He makes a habit of commenting on JAMA articles.
One ex.:
Thanks for sharing hyperopia.
You said:
No worry. We have Erik Ramos, Special Projects, Northwest Biotherapeutics Inc.
June 5, 2023
Importance of conducting clinical trials on the efficacy of DCVax-L for advanced and recurrent glioblastoma in Japan
takuma hayashi, MBBS, DMSci, GMRC, PhD | National Hospital Organization Kyoto Medical Center
Dr. Liau et al reported that in this study, adding DCVax-L to standard of care (SOC) (i.e., temozolomide) resulted in clinically meaningful and statistically significant extension of survival for patients with both newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) compared with contemporaneous, matched external controls who received SOC alone.
In Japan, Avastin (anti-hVEGF monoclonal antibody) is recommended as the first-line drug for treatment against glioblastoma. Subsequently, temozolomide chemotherapy became widely used after randomized controlled trials demonstrated the efficacy of combination therapy with temozolomide and irradiation for glioblastoma, as well as maintenance therapy. However, temozolomide chemotherapy has limited survival benefit.
From December 2019 to April 2023, in cancer genomic medicine at a Japanese national university, new therapies for total of 2991 patients with malignances have been considered by cancer genome testing (Ncc oncopanel test: 679 cases, F1CDx test: 2312 cases). The new therapies for total of 43 advanced and recurrent glioblastomas, including Japanese pediatric patients, were considered by cancer genomic testing. Cancer genomic testing revealed an ATRX pathogenic variant in 32 advanced or recurrent glioblastoma cases. However, ATRX is one of the chromosomal remodeling factors, and antitumor drugs against ATRX pathogenic variants have not been developed.
In Japan, the treatments with DCVax-L for advanced and recurrent glioblastomas was not approved by the Ministry of Health, Labor and Welfare. The efficacy of DCVax-L therapy for advanced/recurrent glioblastoma reported by Dr. Liau et al. have had a major impact on the treatment of advanced and recurrent glioblastoma in Japan. In order to clarify the efficacy of DCVax-L treatment for advanced and recurrent glioblastoma in Japanese, a clinical study with a large cohort should be conducted in Japan in the future.
We do not have potential conflicts of interest.
Dr. Takuma Hayashi, Dr. Ikuo Konishi
National Hospital Organization Kyoto Medical Center
CONFLICT OF INTEREST: None Reported
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847?resultClick=1
Thanks for sharing dstock07734. I agree with your comment. Well said!
I'm confident that the RA's have no problem with the DCVax-L trial design using external data from contemporaneous, matched external controls who received SOC alone .
Thanks dstock07734. Do you have access to this:
https://jamanetwork.com/journals/jamaoncology/article-abstract/2805078
Comment & Response
May 18, 2023
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma
Rifaquat Rahman, MD1; Steffen Ventz, PhD2; Lorenzo Trippa, PhD3
To the Editor We read with interest the results of the autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) externally controlled nonrandomized trial by Liau et al,1 which leverages external data to perform a comparative analysis of DCVax-L survival outcomes in newly diagnosed glioblastoma (GBM). A careful choice of the analysis methods is necessary to avoid biases, which can translate into errors in the regulatory process and potential loss of credibility of future trials that integrate external data.
Rifaquat Rahman is co-author of recent article : Dendritic cell vaccine trials in gliomas: Untangling the lines.
Superb review article that places the recent DCVax study in perspective. pic.twitter.com/PGb9DvRvQG
— Steven Brem (@StevenBremMD) June 9, 2023
Foundation continues support for brain cancer research
The Audley Fund of the Philadelphia Foundation backs Dr. Daniela Bota's search for a glioblastoma cure
June 07, 2023
Laura continues to be inspirational.
If wishing made it so there would be a #Glioblastoma cure but it doesn’t. It requires @DHSCgovuk @CancerResearch @CR_UK @NHSEngland intervention & there is precious little of that.
— Siobhain McDonagh MP (@Siobhain_Mc) June 6, 2023
Hold hands and hum anybody? https://t.co/XyzNnqvlo7
Thank you @SarahOwen_ for raising my daughters case for the second time with the health secretary only for your concerns to be effectively dismissed. This tory government needs to go!! They do not care one bit about my daughter Amani or funding brain cancer Thank you for trying.
— Khuram (@Khuram1972) June 6, 2023
Thank you MP @Siobhain_Mc for putting forward an Early Day Motion in Parliament to honour Laura Nuttall, who passed away 22 May from a #glioblastoma. Read more about what this means and how you can help continue the fight for a world without #braintumours: https://t.co/AL4IxW2Hrh
— The Brain Tumour Charity (@BrainTumourOrg) June 6, 2023
Thanks DWags22! I'm glad to hear she's doing well.
Ronan Rocle
Marketing Manager - Innovative Technologies chez SEQENS
ASCO Day#2
This year’s ASCO annual meeting gathers 43 000 professionals at the congress and 3000 persons for ASCO-related events in Chicago.
ASCO president Eric Winer gave an inspirational speech, sharing his experience and lessons learned both as a prominent oncologist and as an haemophilia patient.
Monica Bertagnolli, National Cancer Institute director and recipient of the Allen Lichter visionary leader award, presented the levers to achieve the « Cancer Moonshot » objective to reduce by half cancer mortality in the next 25 years. She also showed the tremendous and regular decrease of breast cancer mortality in the US since 1990 (while it was stable before).
In the poster presentation session « Developmental therapeutics - Molecularly targeted agents and tumor biology », Wells Messersmith presented several promising small molecules under development (« Small molecules: ready for the big game ? »), such as Tinengotinib, a 2nd generation FGFR inhibitor with a unique binding mode allowing to overcome resistance to 1st generation inhibitors, or TTI-101, a small molecule STAT inhibitor.
Marnix Bosch, CTO of Northwest Biotherapeutics, presented the phase III results of DCVax-L, a cancer vaccine based on autologous dendritic cells incubated with the patient’s tumor lysate.
DCVax-L was developed against glioblastoma, a brain cancer which has limited treatment options. Several patients in remission following this treatment were present in the audience.
https://www.linkedin.com/feed/update/urn:li:activity:7070988337045467136/
More and more patients with glioblastoma who really wants a chance to live, are trying to get early treatment with DCVax-L and possibly live years beyond their previous fatal diagnosis.
#DCVax pic.twitter.com/4NRUJ6lttq
— Peter Davis (@peter_brit) June 4, 2023
“Tumor lysate-loaded DCs (DCVax-L) have acquired additional T cell stimulatory capacity, resulting in more late generation T cells to fight the tumor” -Marnix Bosch #asco2023 #dcvax $nwbo pic.twitter.com/x6gn4IaQvq
— Allen Turner (@AllenTurner206) June 3, 2023
Getting ready to listen to a presentation on the DC-Vax in Industry Theater 1. Come join us to hear some new information! Met up with CEO Linda Powers before the session! #ASCO23 @NorthwestBio @EndBrainCancer pic.twitter.com/GjHeKQ3bPM
— EndBrainCancer Initiative (@EndBrainCancer) June 3, 2023
False narrative. Anyway, on Feb. 6, 2017 NWBio announced that the partial clinical hold on the Trial has been lifted by the FDA.
At a workshop at the National Academy of Sciences, Engineering and Medicine in 2017, Janet Woodcock, director of the FDA Center for Drug Evaluation and Research was quoted as saying the clinical trials system is “broken,” and new ways to collect and utilize patient data are needed.
https://endpts.com/fdas-janet-woodcock-the-clinical-trials-system-is-broken/
FDA 2018